Avivo Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 8

Avivo General Information

Description

Developer of a health-tech platform intended to make blood groups irrelevant for transfusion or organ transplant. The company's platform uses a proprietary technology that is a combination of two enzymes that first prime and then eliminate a marker on the red blood cell that determines blood group A, enabling hospitals to use any blood type for any patient safely.

Contact Information

Formerly Known As
ABOzymes, ABOzymes Biomedical
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 595 Burrard Street
  • Suite 2600, Post Office Box 49314
  • Vancouver, British Columbia V7X 1L3
  • Canada
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 595 Burrard Street
  • Suite 2600, Post Office Box 49314
  • Vancouver, British Columbia V7X 1L3
  • Canada

Avivo Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avivo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Accelerator/Incubator 01-Jan-2026 Completed Pre-Clinical Trials
7. Accelerator/Incubator 10-Dec-2025 Completed Pre-Clinical Trials
6. Grant 31-Mar-2022 Completed Pre-Clinical Trials
5. Seed Round 31-Mar-2022 Completed Pre-Clinical Trials
4. Grant Completed Pre-Clinical Trials
3. Seed Round 28-Feb-2021 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2021 Completed Startup
1. University Spin-Out 01-Jan-2020 Completed Startup
To view Avivo’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Avivo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avivo Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Scale Up Canada Accelerator/Incubator
Diana (UK) Accelerator/Incubator
Genome British Columbia Not-For-Profit Venture Capital
Little Green Bamboo Capital Venture Capital Minority
WUTIF Capital Angel Group Minority
You’re viewing 5 of 8 investors. Get the full list »

Avivo FAQs

  • When was Avivo founded?

    Avivo was founded in 2020.

  • Where is Avivo headquartered?

    Avivo is headquartered in Vancouver, Canada.

  • What is the size of Avivo?

    Avivo has 14 total employees.

  • What industry is Avivo in?

    Avivo’s primary industry is Biotechnology.

  • Is Avivo a private or public company?

    Avivo is a Private company.

  • What is Avivo’s current revenue?

    The current revenue for Avivo is .

  • How much funding has Avivo raised over time?

    Avivo has raised $3.23M.

  • Who are Avivo’s investors?

    Scale Up Canada, Diana (UK), Genome British Columbia, Little Green Bamboo Capital, and WUTIF Capital are 5 of 8 investors who have invested in Avivo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process